Trials / Recruiting
RecruitingNCT04986657
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
A Prospective Study of Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 325 (estimated)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnoses of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | ChromoSeq | Novel, streamlined whole genome sequencing approach |
Timeline
- Start date
- 2021-09-17
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2021-08-03
- Last updated
- 2025-10-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04986657. Inclusion in this directory is not an endorsement.